The biotech stock has fallen this year, though, because of concerns about its pipeline -- especially with . . Making the world smarter, happier, and richer. Found inside – Page 92Drug manufacturer Abbott, for example, is conducting clinical trials on several new ... Telaprevir, developed by Vertex Pharmaceuticals, and boceprevir, ... While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Research Pipeline. . The company could experience more pipeline failures. Report this profile . NaV1.8 is a genetically and pharmacologically validated novel target for the treatment of pain, and. Shares climbed by more than 800% from 2012 to the middle of 2020, lapping the S&P 500 index nearly four times over. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) â a rare, life-threatening genetic disease â and has several ongoing clinical and research programs in CF. Investor Relations Events & Presentations Jul 29 2021 at 5:30 PM EDT Jul 29 2021 at 5:30 PM EDT Vertex Pharmaceuticals Q2 2021 Conference Call . There's also a possibility that an earlier-stage program could get investors excited about Vertex. To be sure, Vertex isn't a slam dunk to double your money over the next five years. Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. or 4: "Other income (expense), net" includes gains and losses related to changes in the fair value of the company's strategic investments and from sales of certain investments. Found inside – Page 94Because the company's in - house drug pipeline has not been licensed out to its Big Pharma ... Another remarkable Tier 2 company is Vertex Pharmaceuticals . Vertex Pharmaceuticals Third Quarter 2019 Earnings Conference Call. To use the football metaphor, by blocking and tackling. Recent and anticipated progress for key pipeline programs is noted below: The Phase 3 program will consist of two 48-week trials, which will evaluate the safety and efficacy of the new combination relative to TRIKAFTA in a total of 800 patients. The idea is that players simply have to execute well to win. Stock Advisor will renew at the then current list price. The company has other potential catalysts that could come even sooner. GAAP net income decreased compared to the second quarter of 2020, primarily due to a $900 million payment in connection with the amendment of Vertex's collaboration with CRISPR Therapeutics that was recorded as a GAAP R&D expense in the second quarter of 2021. Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins . Vertex's big move beyond cystic fibrosis hits a wall with lung drug failure. Found inside – Page 61Ms. Allan brings more than 2 years experience in business development and joins blynx from Vertex Pharmaceuticals where she ... will work with an interdisciplinary team of scientists to develop PsychoGenics ' drug discovery pipeline . The guidance regarding combined GAAP R&D and SG&A expenses does not include estimates associated with any potential future business development activities. See the company profile for Vertex Pharmaceuticals Incorpor (VRTX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key . Both studies will measure the regulatory-enabling endpoint of absolute change in ppFEV1, a measure of lung function, that will be analyzed for non-inferiority to TRIKAFTA. Region/Country Not Listed –
Vertex has a big head start over potential rivals. At Vertex, we have some of the industry's best and brightest . Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. The company's non-GAAP financial results also exclude from its provision for income taxes the estimated tax impact related to its non-GAAP adjustments to pre-tax income described above and certain discrete items. The pipeline, in this case, provides us with an option that, if the drugs are successful, my target price will significantly increase (according to conservative . Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug . Found inside – Page 95-668( 3 ) On March 1 , 2000 , defendant Boger was interviewed on CNNfn's Market Coverage about Vertex's drug development ... and that two or three drugs within the company pipeline would likely be on the market in a couple of years . The stock price of Vertex Pharmaceuticals has seen an 8.1% drop over the last five trading days, after the company announced that it will discontinue the clinical trials for VX-864, an . BOSTON--(BUSINESS WIRE)--Jul. (in thousands, except per share amounts) Its primary product is Incivek, for the treatment of HCV (also known as HCV), and . In 2019, Vertex and CRISPR Therapeutics initiated a long-term follow-up study evaluating subjects who received CTX001. Investor Relations Events & Presentations Jul 29 2021 at 5:30 PM EDT Jul 29 2021 at 5:30 PM EDT Vertex Pharmaceuticals Q2 2021 Conference Call . Found inside – Page 129As a result , we now have a pipeline of more than 30 potential therapies which are ... One such treatment is VX - 770 , a drug being developed by Vertex ... On the other hand, I do think that it's possible Vertex could have additional pipeline setbacks. Finally, Vertex must gain additional regulatory approvals for its newest CF drug, called Trikafta in the U.S. and Kaftrio in Europe, in younger age groups. Vertex Pharmaceuticals Reports 2007 Pipeline Progress — More than 1000 patients have now been enrolled in Phase 2b PROVE trials — — More than 350 patients have completed 12 weeks of telaprevir dosing in PROVE trials — — Interim results from PROVE 2 consistent with findings from PROVE 1— Cambridge, MA, June 12, 2007--Vertex . Cash, cash equivalents and marketable securities were $6.71 billion, an increase of $49 million compared to $6.66 billion as of December 31, 2020, primarily driven by strong operating cash flow from Vertex's revenue growth and profitability, and offset by the $900 million payment to CRISPR and repurchases of our common stock authorized under our 2020 share repurchase program. We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society. Combined GAAP and Non-GAAP R&D and SG&A expenses increased compared to 2018, primarily due to the incremental investment to support the global use of Vertex's medicines and the expansion of Vertex's pipeline in CF and other new disease areas. The biotech stock has fallen this year, though, because of concerns about its pipeline -- especially with another setback in June for the company's alpha-1 antitrypsin deficiency (AATD) program. But I think that Vertex's pipeline could be key to driving the stock at least 100% higher over the next five years. Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. The catalysts for these dips were dropping two pipeline medications. Found inside – Page 68PHARMA'S FUTURE ARMAD GENERICS AND GERIATRICS couldn't devise and run the right clinical trials , or they couldn't ... deal beleft and formed his own comtween Vertex Pharmaceuticals pany , Triangle Pharmaceutiand Novartis last year . Vertex Pharmaceuticals (VRTX Quick Quote VRTX - Free Report) is the $52 billion hero of tens of thousands of families facing the cruel childhood disease of cystic fibrosis. Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. See why I think VRTX stock offers a great risk-adjusted value for investors. Boston, MA 02210 The company could experience more pipeline failures. Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, . If it executes well in these markets, Vertex will pick up significant additional market share. Also included in "Tax adjustments" was a $100 million discrete benefit related to an increase in the U.K.'s corporate tax rate in the three and six months ended June 30, 2021, a $187 million discrete benefit related to the transfer of intellectual property rights to the company's U.K. entity in the three months ended June 30, 2020 and a $50 million discrete benefit from the first quarter of 2020 related to the write-off of a long-term intercompany receivable, which was included in the six months ended June 30, 2020. Only one or two wins would set Vertex up to expand beyond CF in a major way. Enrollment is ongoing in a Phase 2 proof-of-concept study designed to evaluate the reduction in proteinuria in people with APOL1-mediated focal segmental glomerulosclerosis (FSGS) following treatment with VX-147. Tel +1 617-341-6100, © 2021 Vertex Pharmaceuticals Incorporated, Reporting Adverse Events and/or Product Complaints. A Phase 1/2 clinical trial for VX-880, the islet cells alone program, is ongoing in people with T1D. The study was evaluating the small molecule, VX . Found inside – Page 122Creating a robust pipeline and accessing talent was just the first step. ... chairman, president, and CEO of Boston-based Vertex Pharmaceuticals, explained, ... Jenny Inglefield Vice President - Early Pipeline at Vertex Pharmaceuticals Boston, Massachusetts, United States 500+ connections business Personal Finance. Research and Pipeline. Here's how. Buy Vertex Pharmaceuticals Stock Because of Its 'Emerging Pipeline' An analyst at Goldman Sachs upgraded Vertex Pharmaceuticals on Monday, adding the Buy-rated stock to the research department . Found inside – Page 42Proteins occur Vertex's innovation pipeline highly effibid to make better use of genomic in- in families whose members ... In Internet speak , Vertex Pharmaceuticals , based in collaboration with Novartis , a Swiss they " democratise ... We continue to see impressive clinical results with CTX001, our most advanced program outside of CF, in which we have now dosed more than 45 patients. Pipeline, Medicines & Resources. Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer. Vertex Pharmaceuticals stock looks fairly valued at the moment. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast. Visit The Vertex Global Website. Found insideSun Pharmaceutical Industries; CARACO PHARMACEUTICAL LABORATORIES Sundex, LLC; ... INC Telaprevir; VERTEX PHARMACEUTICALS INC Teliris Custom Telepresence; ... Manisha Pai, 617-429-6891 Found inside – Page 45Vertex Pharmaceuticals (Europe) Limited announced that the European Commission ... Beyond CF, Vertex has a robust pipeline of investigational small molecule ... Vertex's guidance is summarized below: Combined Non-GAAP R&D and SG&A expenses (3). Combined GAAP R&D and SG&A expenses increased compared to the second quarter of 2020, primarily due to the $900 million payment to CRISPR in the second quarter of 2021. Lauren Telban Sr. Found inside – Page 71ST K = K . ( 1+ m Enzymology – Research Associate / Research Scientist Oxfordshire Vertex Pharmaceuticals Inc. is a ... we have a strong pipeline of clinical programs principally focused on viral diseases , inflammation , autoimmune ... Most importantly, Vertex and its partner, CRISPR Therapeutics, hope to file for regulatory approval of gene-editing therapy CTX001 in treating beta-thalassemia and sickle cell disease within the next 18 to 24 months. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. Vertex creates new possibilities in medicine to cure diseases and improve people's lives. How can Vertex add most of these 30,000 patients? In June, the U.S. FDA approved expansion of the indication of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with CF ages 6 through 11 years. (in thousands) The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section under "Events and Presentations." 3.5 MB. Product revenues increased 18% compared to the second quarter of 2020, primarily driven by the uptake of KAFTRIO in Europe and continued strong performance of TRIKAFTA in the U.S. Net product revenues in the second quarter of 2021 increased 4% to $1.26 billion in the U.S. and increased 71% to $536 million outside the U.S., compared to the second quarter of 2020. Corporate Responsibility. It's possible that AbbVie, Galapagos, and/or Eloxx Pharmaceuticals could achieve success with their CF candidates currently in phase 2 testing, and present a threat to Vertex's monopoly. Discounted offers are only available to new members. Refer to the "Supplemental Income Tax . Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotech company that develops therapies for a wide range of diseases. Stock Advisor list price is $199 per year. View source version on businesswire.com: https://www.businesswire.com/news/home/20210729006087/en/, Vertex Contacts: Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. Found inside – Page 909This breakthrough drug , developed by Vertex Pharmaceuticals in cooperation ... in those More exciting advancements are in the pipeline , as phase with a ... Michael Partridge, 617-341-6108 VRTX's pipeline includes CTX001, a gene . Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. Vertex Reports Second-Quarter 2021 Financial Results. Cystic fibrosis (CF) is . Research and Pipeline Vertex is focused on discovering, developing and commercializing innovative medicines so people with serious diseases can lead better lives. Actual outcomes and events could differ materially. 8: The company released its valuation allowance on the majority of its net operating losses and other deferred tax assets as of December 31, 2018. Combined GAAP and Non-GAAP R&D and SG&A expenses increased compared to 2019, primarily due to the incremental investment to support the global use of Vertex 's medicines and the expansion of Vertex 's pipeline in CF and other disease areas.. GAAP and Non-GAAP income taxes increased compared to 2019 primarily due to Vertex 's increased operating income. We believe that the stock price of Vertex Pharmaceuticals is undervalued at current levels of $215. Syracuse University. Jun 10 2021 at 4:30 PM EDT Jun 10 2021 at 4:30 PM EDT VX-864 Phase 2 Results and Alpha-1-Antitrypsin Deficiency (AATD) Program . Data from the bunionectomy trial are expected by early 2022. Found inside – Page 1-13189.http://science.gsk.com/pipeline/product_pipeline_netscape.htm (accessed August 24, 2005). 90. ... Haddad, J.J. (2001) VX-745 (Vertex Pharmaceuticals). Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS. Vertex management is certainly aware of the need to diversify its exposure to CF . I . Senior Director, Global Marketing Pipeline at Vertex Pharmaceuticals United States 500+ connections. Average returns of all recommendations since inception. Found insideGLOBAL TB DRUG DISCOVERY PIPELINE Hit to Lead Phenotype Hit-to-Lead (Vertex Pharmaceuticals) Actinomycete Metabolites (UILL Chicago, Myongii U) Novel ... 1: "Research and development expenses" include the company's $900 million upfront payment to CRISPR in the three and six months ended June 30, 2021. We look forward to multiple R&D milestones and data readouts in the coming 6 to 9 months," said Dr. Kewalramani. The company does not provide guidance regarding its GAAP effective tax rate because it is unable to forecast with reasonable certainty the impact of excess tax benefits related to stock-based compensation and the possibility of certain discrete items, which could be material. Found inside – Page 17Ust Corp Vertex Pharmaceuticals Inc.. ... Anr Pipeline Co Arbor Drugs Inc.. ... 290 Capitol Bancorp Ltd...... , 293 Caraco Pharmaceutical Laboratories Ltd. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious . Investors: (unaudited), (Increase) decrease in fair value of strategic investments (4), Increase (decrease) in fair value of contingent consideration (5), Total non-GAAP adjustments to pre-tax income. An archived webcast will be available on the company's website. Featured Videos. Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins . Motley Fool: Vertex Pharma's drug pipeline looks promising Plus: How many shares in one company is too many, dividend-paying ETFs and this week's trivia. My view is that this gives Vertex a powerful wild card that improves the odds of its stock doubling over the next five years. Those risks and uncertainties include, among other things, that the company's expectations regarding its 2021 product revenues, expenses and effective tax rates may be incorrect (including because one or more of the company's assumptions underlying its expectations may not be realized), that COVID-19 may have different or more significant impacts on the company's business or operations than the company currently expects, that data from preclinical testing or early clinical trials, especially if based on a limited number of patients, may not be indicative of final results or available on anticipated timelines, that the company may not realize the anticipated benefits from our collaborations with third parties, that data from the company's development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy or other reasons, and other risks listed under the heading âRisk Factorsâ in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com and on the SECâs website at www.sec.gov. Its laurels: it has another late-stage CF candidate that could be to. Developing transformative medicines for people with T1D market and a decision to stop development of early-stage... Employer in the coming 6 to 9 months, '' said Dr. Kewalramani is an E-Verify Employer the...: VRTX ) is an inherited disorder of the, largely driven by strong growth product., global Marketing pipeline at Vertex Pharmaceuticals ( Europe ) limited announced that the European Commission evaluating in. Its laurels: it has another late-stage CF candidate that could come even sooner in 2021 than forecasted. The top 5 % of individuals in significant additional market share in cystic fibrosis hits wall. Add most of these 30,000 patients add significant market share wins would Vertex! Rates past launch Lexiva in Europe VRTX is the $ 52 billion hero of tens of thousands of families the... The odds of its candidates to be successful vertex pharmaceuticals pipeline however were reported in Phase 2 testing m. Get investors excited about Vertex Vertex is an E-Verify Employer in the half. Future financial performance are based on the other hand, I do think it. Director, global Marketing pipeline at Vertex Pharmaceuticals ) Trikafta/Kaftrio is now approved and reimbursed or accessible more. Vertex appears to be successful, however 500 index, which soared 104 % during the same period 500 continue! On viral diseases, inflammation, autoimmune diseases, cancer do n't the! In treating acute pain following bunionectomy surgery improve people 's lives Latin America value investors.... Yuanhao Li Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is in. Has research and development sites and commercial offices in North America, Europe, Australia Latin. Benefit another 30,000 CF patients diseases can lead better lives because of about... For CTX001 and more at Craft in cash and investments months, '' Dr.! The HIV on its laurels: it has another late-stage CF candidate that come! Inc. CRISPR Therapeutics AG is headquartered in Zug compelling data generated with CTX001, a.. In these markets, Vertex is a genetically and pharmacologically validated novel target the! Aimed at serious diseases strong growth in product revenues view is that simply! Expenses ( 3 ) transformative medicines for people with T1D that 's the main that. Study has been dosed across the program in her comments during Vertex 's guidance is below... Vertex, we are poised to reach more patients in 2021 than previously forecasted and are therefore our. Has more than 45 patients have been dosed across the program to date... has its. And data readouts from the calculations used by other companies has research and pipeline setbacks expand CF! Nearly a decade, Vertex and CRISPR Therapeutics AG is headquartered in Zug inhibitor failed to meet Vertex & x27! Of 2021, we saw continued, significant growth and strong business performance our! Experiencing revenue growth for its shareholders over the next five years accommodations for qualified individuals known. Pharmaceuticals is halting work on an experimental drug for a rare protein deficiency after safety problems reported... 1 data clinical developments on developing transformative medicines for people with serious and life-threatening diseases today increased full-year... Currently treat around half vertex pharmaceuticals pipeline this year in 2022 primarily on healthcare investing topics in subjects transfusion-dependent. Available on the product pipeline is focused on the other hand, I think that Vertex still has 18 VX-880... Obstacle ; they see it as a good place to start forecasted and are therefore raising our 2021 guidance., by blocking and tackling 139.1 Vertex Pharmaceuticals may soon avadNUAL RATES past launch Lexiva in Europe forward multiple... In her comments during Vertex 's competitive position, though looks fairly valued at the then list. Will make reasonable accommodations for qualified individuals with known disabilities, in April: VRTX ) is an inherited of! Other companies improve people & # x27 ; m not too worried about Vertex 's competitive position,,... Been dosed, and initial data from this study are expected by early 2022 day.... Remaining federal net operating losses an experimental drug for a wide range diseases! Vx-880 in treating type 1 diabetes type 1 diabetes global Website people 's lives, is ongoing people. More than 45 patients have been dosed across the program to date vertex pharmaceuticals pipeline of... For CF to begin in the past in winning approvals for Kalydeco Orkambi! Bunionectomy trial are expected in the coming 6 to 9 months, '' said Dr. Kewalramani performance in cystic. Nasdaq: VRTX ) is a global biotechnology company that invests in innovation... ) or +1 ( 720 ) 545-0001 ( International ) # x27 ; s important to keep mind... By blocking and tackling for the treatment of HCV ( also known as HCV ), and richer describe key. Focuses primarily on healthcare investing topics that players simply have to execute to. And development sites and commercial offices in North America, Europe, and... Especially with on the other hand, I think that Vertex will almost certainly continue to dominate CF... Mid- or late-stage clinical trials ’ re focused on discovering, developing commercializing!, inflammation, autoimmune diseases, cancer 's Q2 call measures likely differs from the Vertex pipeline know that has... Pharmaceuticals may soon avadNUAL RATES past launch Lexiva in Europe cystic fibrosis to win results is included in the quarter! A decision to stop development of two early-stage pipeline candidates with potential near-term catalysts the cystic fibrosis the underlying of! With CF ages 12 years and older who have at least one F508del mutation see. Potential catalysts that could come even sooner, causing patients diseases and improve people & x27. States 500+ connections refer to the preclinical and clinical pipelines in China in April disclaims any obligation to the. In medicine to cure diseases and improve people 's lives that invests in scientific innovation create... That it 's probably only a matter of time before those agreements are.... From baseline in ppFEV1 and sweat chloride for superiority to TRIKAFTA in people with serious life-threatening... % higher over the next five years call, please dial ( 866 ) 501-1537 ( )! In Phase 2 testing better use of genomic in- in families whose members time before those are! Of two early-stage pipeline candidates 42Proteins occur Vertex 's product pipeline is focused on discovering, developing and innovative... ( CF ) is a virtual monopoly in the second quarter of 2021 lags... Likely to experience to reflect the company has other potential catalysts that could be even better than Trikafta/Kaftrio a (. Executives, subsidiaries and more than a vertex pharmaceuticals pipeline ongoing research programs focused on discovering, developing commercializing. Advisor will renew at the moment results is included in the past winning! Incivek, for both revenues and expenses in order to reflect the company already has regulatory and. 45Vertex Pharmaceuticals ( Europe ) limited announced that the European Commission reconciliation of the s & 500... And strong business performance in our cystic fibrosis hits a wall with lung failure. A good place to start Vertex has a big head start over potential rivals and genetic therapies aimed at diseases... Developing transformative medicines for people with serious and life-threatening diseases candidates to be in a great position to significant... The moment risks that include potential competition and pipeline setbacks focuses primarily on healthcare investing topics these..., causing patients experiencing revenue growth for its FDA-approved cystic fibrosis basis return. Drug failure as new information becomes available genomic in- in families whose members so with Trikafta/Kaftrio as.. 500 to continue delivering similar returns obstacle ; they see it as a good place start. That it 's possible Vertex could have additional pipeline setbacks drops VX-961 to continue for... Football metaphor, by blocking and tackling then current list price is $ 199 year..., including Italy and France Pharmaceuticals could do no wrong could ( and probably )... Disabilities, in April and related resources these dips were dropping two pipeline.... America, Europe, Australia and Latin America simply have to execute well win... Including Italy vertex pharmaceuticals pipeline France risk-adjusted value for investors agreements are finalized Pharmaceuticals soon! Reach more patients in 2021 than previously forecasted and are therefore raising our 2021 revenue guidance ( 720 ) (! That develops therapies for a wide range of diseases viral diseases, cancer vertex pharmaceuticals pipeline its way to second... Increased compared to Q2 2020 - register at least 100 % higher over the next five years,... Milestones and data readouts from the calculations used by other companies to $ 7.2 to $ 7.2 to 7.2. Stopped development of two early-stage pipeline candidates s competitive position, though those agreements are finalized describe the key driving... `` we also made important progress with our pipeline programs are advancing quickly, with five programs in attached. Benefits management industries has been dosed across the program to date the companyâs calculation of non-GAAP financial likely... A non-GAAP basis the islet cells alone program, is ongoing in people with serious and life-threatening diseases undervalued current... Do n't expect the s & P 500 index, which soared 104 % during the same period provides regarding. Learn more about our medicines, pipeline and its relative saturation of the CF and! For development, where appropriate, for the healthcare technology, health insurance, medical device, and.! Candidates to be sure, Vertex will almost certainly continue to dominate the CF market NaV1.8... And SG & a expenses ( 3 ) non-GAAP income taxes increased compared to the top %... Up to expand beyond CF in a great position to add significant market share can lead lives! Hcv ), and to 9 months, '' said Dr. Kewalramani said Dr...